President Trump signaled major price reductions for Novo Nordisk's Ozempic, potentially lowering costs to $150. This announcement, made amid ongoing drug price negotiations, caused significant drops in pharma stock prices.
Novo Nordisk acquired the rare disease drug zaltenibart from Omeros for up to $2.1B. It treats disorders like PNH & Novo plans Phase 3.
FDA flags Catalent facility producing Regeneron's EYLEA HD syringe. Canaccord maintains $850 target, highlighting Alzheimer's pipeline potential and GLP-1 combos.
Novo Nordisk has agreed to acquire clinical-stage Akero Therapeutics for up to $5.2 billion to integrate efruxifermin (EFX), a promising late-stage treatment for MASH, complementing Novo Nordisk's leadership in cardiometabolic disease.
Novo Nordisk is planning a strategic digital launch for its forthcoming obesity pill, targeting telehealth sites like Ro and WeightWatchers in early 2026 to recapture market share lost to rival Eli Lilly and combat the rise of copycat drugs.
GoodRx and Kroger launched RxSmartSaver at 2,200 pharmacies. Scan a code for instant discounts on brand drugs like Ozempic and Lantus.
